StreetAlpha.app
Home › Stocks › DHR

Danaher Corp (DHR)

Healthcare
$220.36
▼ −3.16%
LAST CLOSE · NOV 20

Danaher makes and sells medical devices, laboratory products and related services to healthcare and research customers worldwide. It last closed at $220.36 on Nov 20, down 3.16% on the day. The next earnings report for DHR is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, DHR reported EPS of $1.75 on revenue of $6.55B, with revenue up 8.3% from a year ago. Over its last 8 reports the stock moved an average of 3.5% the session after earnings. Over the last 12 months DHR insiders bought $0 of stock on the open market and sold $36.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is DHR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DHR.

Key Stats

Last 12 months
Results
Revenue
$25.6B
+5.5% vs a year ago
Net income
$4.3B
+23.6% vs a year ago
EPS (diluted)
$6.10
+25.5% vs a year ago
Free cash flow
$5.7B
22.4% margin
Valuation
Market cap
$155B
703.5M shares
P/E
36.1
Price over 12 month EPS
Price to sales
6.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.7B
At Sep 25
Debt
$26.5B
At Sep 25
Shareholder equity
$53.6B
Buybacks
$894.0M
Last 12 months
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $24.8B$24.8BFY2021FY2022: $26.6B$26.6BFY2022FY2023: $23.9B$23.9BFY2023FY2024: $23.9B$23.9BFY2024FY2025: $24.6B$24.6BFY2025

From DHR's SEC filings, latest 10-Q for the period ending Sep 25, 2026 (filed Oct 21). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$1.75
Quarter ended Sep 2026
Year ago EPS
$1.27
+37.8% on a GAAP basis
Revenue
$6.55B
+8.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.49Dec '24Mar 2025: $1.32Mar '25Jun 2025: $0.77Jun '25Sep 2025: $1.27Sep '25Dec 2025: $1.68Dec '25Mar 2026: $1.45Mar '26Jun 2026: $1.23Jun '26Sep 2026: $1.75Sep '26Latest $1.75
Revenue by quarter
Dec 2024: $6.54BDec '24Mar 2025: $5.74BMar '25Jun 2025: $5.94BJun '25Sep 2025: $6.05BSep '25Dec 2025: $6.84BDec '25Mar 2026: $5.95BMar '26Jun 2026: $6.26BJun '26Sep 2026: $6.55BSep '26Latest $6.55B
How DHR moved after its last 8 reports
Average move the session after a report ±3.5%
Oct 20, 2026After the close+4.3%
Jul 20, 2026After the close−11.0%
Apr 20, 2026After the close−0.5%
Jan 12, 2026Time not announced+0.3%
Oct 20, 2025After the close+5.9%
Jul 21, 2025After the close+1.0%
Apr 22, 2025Time not announced+3.8%
Jan 13, 2025After the close−0.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DHRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DHR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DHR

Technical Analysis

DHR · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 5% below its 20 day and 2% below its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the swing low (Oct 21) at $217.55, and the nearest resistance the swing high (Aug 20) at $220.67.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 2.8%/day
Key levels
$242.8052 week high+10.2%
$231.0920 day average+4.9%
$225.71Pivot R1+2.4%
$224.7850 day average+2.0%
$222.82Pivot+1.1%
$220.67Swing high (Aug 20)+0.1%
$220.36Last close
$217.55Swing low (Oct 21)−1.3%
$217.46Pivot S1−1.3%
$213.58100 day average−3.1%
$201.19200 day average−8.7%
$160.9352 week low−27.0%
Indicators
RSI (14)40.95Middle of its rangeNeutral
MACD0.31Below its signal lineBearish
Stochastic22.8Middle of its rangeNeutral
ADX (14)20.0No clear trend
Williams %R-97.6Oversold below −80, overbought above −20Oversold
CCI (20)-216.2Oversold below −100, overbought above 100Oversold
Rate of change−4.3%Change over 10 sessionsBearish
ATR (14)$6.15Typical daily range, 2.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for DHR

What happened before

See how DHR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DHR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DHR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DHRHow many large options trades hit DHR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

DHR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●966 buying vs 1,014 selling
  • ●Held by funds -0.3 pts
  • ▲Funds holding +91
  • ▼Superinvestors: 4 added, 6 cut
  • ▼Put/call 0.35 to 0.41
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2,2112,120+4.3%
In funds' top 106041+46.3%
Held by funds81.9%82.2%−0.3 pts
New / increased232 / 734134 / 670+20.1%
Reduced / sold out895 / 1191,015 / 195−16.2%
Put/call ratio0.410.35+19.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DHR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DHR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$36.0M8 sales · 6 insiders
2026-02 sold $275K2026-05 sold $237K2026-08 sold $12.7M2026-10 sold $8.8M2026-11 sold $4.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 9Gregory M MilosevichExecutive Vice PresidentSale2,100$230.62$484K
Nov 9Matthew McGrewExecutive Vice PresidentSale17,385$235.69$4.1M
Oct 28Matthew McGrewExecutive Vice PresidentSale29,754$235.74$7.0M
Oct 28Christopher BoudaVP, Chief Accounting OfficerSale7,598$234.56$1.8M
Aug 21Rainer BlairPresident & CEOSale58,255$218.63$12.7M
May 1Alan G SpoonDirectorSale1,358$174.67$237K
Every insider buy and sale for DHR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DHR insider trades →

From SEC Form 4 filings by DHR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

DHR Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$894.0M
0.6% yield
Left in program
32.0M sh
4.5% of shares
Shares outstanding, 12 months
−0.4%
Fewer shares
Last quarter
—
Sep 2026
Avg price paid, last quarter
—
 
S&P 500 rank by spending
#205 of 358
 
Spent each quarter, last 3 yearsTop bar $4.5B
Dec 2023: $0Mar 2024: $0Jun 2024: $4.5B, average price $259.86Sep 2024: $639.9M, average price $249.40Dec 2024: $808.5M, average price $231.99Mar 2025: $1.1B, average price $238.69Jun 2025: $0Sep 2025: $2.0B, average price $201.00Dec 2025: $0Mar 2026: $0Jun 2026: $893.6M, average price $178.71Sep 2026: $0
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 21, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DHR is in one of them and how their past DHR trades turned out.

DHR in the AI portfolios
Loading…

DHR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DHR in an article yet. Here's the latest on the wider market.

DHR in the news

DHR Congress Trades

All congress trades →
Trades, 12 months
7
Buys
3
43%
Sells
4
57%
People
5
Last filed Nov 5
Who traded DHR · since 2014
Latest 5 filings of 131
$1K – $15KTraded Oct 13, 2026Filed Nov 5, 2026
Kevin HernSell (partial)
$1K – $15KTraded Sep 2, 2026Filed Sep 25, 2026
$15K – $50KTraded Aug 31, 2026Filed Sep 25, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
$1K – $15KTraded Dec 18, 2025Filed Jan 15, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CABuy$1K – $15KOct 13, 2026Nov 5, 202623 d
Kevin HernR · OKSell (partial)$1K – $15KSep 2, 2026Sep 25, 202623 d
Kevin HernR · OKSell$15K – $50KAug 31, 2026Sep 25, 202625 d
Alan ArmstrongR · OKBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d
Julie JohnsonD · TXSell$1K – $15KDec 18, 2025Jan 15, 202628 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Danaher

Danaher is based in Washington, DC. It makes and sells medical devices, laboratory products and related services used in healthcare and research settings. Its customers include hospitals, clinical laboratories, research organizations and private and government payors. Most of its sales come from customers outside the United States, and many of its manufacturing operations are located abroad.

Headquarters
Washington, DC
Founded
1981